ArticleCardiovascular diabetology2016
Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
Article in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The association between diabetes and abdominal aortic aneurysms in men: results of two Danish screening studies, a systematic review, and a meta-analysis of population-based screening studies.BMC cardiovascular disorders · 2023Pooled it
- The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review.Vascular medicine (London, England) · 2022Pooled it
- Association Between Metformin and Abdominal Aortic Aneurysm: A Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021 · on this mapPooled it
- Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets.Annals of human genetics · 2026 · on this mapObservational
- Metformin Use and Long-term Outcomes Including Aneurysm Sac Dynamics Following EVAR for Infrarenal Abdominal Aortic Aneurysm: "A Retrospective Study".Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2026Article
- Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors.Journal of the American Heart Association · 2025Article
- Proteinuria is risk factor for abdominal aortic aneurysm: a nationwide population-based study.BMC public health · 2025Article
- Hyperglycemia inhibits AAA expansion: examining the role of lysyl oxidase.American journal of physiology. Heart and circulatory physiology · 2025Article
- Risk factors for thoracic aortic aneurysm and dissection among diabetic patients: a nationwide population-based study.Frontiers in cardiovascular medicine · 2025Article
- Metformin Therapeutic Targets for Aortic Aneurysms: A Mendelian Randomization and Colocalization Study.Reviews in cardiovascular medicine · 2024Article
- Treatment With Small Molecule Inhibitors of Advanced Glycation End-Products Formation and Advanced Glycation End-Products-Mediated Collagen Cross-Linking Promotes Experimental Aortic Aneurysm Progression in Diabetic Mice.Journal of the American Heart Association · 2023Article
- Mechanisms and efficacy of metformin-mediated suppression of established experimental abdominal aortic aneurysms.JVS-vascular science · 2023Article
- Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?Frontiers in cardiovascular medicine · 2023Review
- Chronic Thoracic Aortic Dissection: How to Treat, When to Intervene.Life (Basel, Switzerland) · 2022Review
- The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma.Frontiers in cardiovascular medicine · 2022Article
- Lower risk of subarachnoid haemorrhage in diabetes: a nationwide population-based cohort study.Stroke and vascular neurology · 2021Article
- Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms.Journal of atherosclerosis and thrombosis · 2021Review
- Sex Differences in Rupture Risk and Mortality in Untreated Patients With Intact Abdominal Aortic Aneurysms.Journal of the American Heart Association · 2021Article
- Exploring the Correlation and Protective Role of Diabetes Mellitus in Aortic Aneurysm Disease.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleiotropic effects on cardiovascular protection have been suggested in several oral antidiabetic drugs (OAD). The impacts of OADs on aortic aneurysm (AA) growth have been found in animal studies, but the evidence of their beneficial effects for AA protection in human are lacking. We investigated the relationship between OAD therapy and the risk of developing AA.
methodsWe conducted a nested case-control analysis using the database extracted from Taiwan's National Health Insurance Research Database. The database consists of 1.2 million diabetic patients representing the majority of the type 2 diabetes population in Taiwan from 2000 to 2013. Cases were identified as those with either inpatient or outpatient diagnosis code of AA. One control was selected for each case matching on duration of follow-up, age, sex, urbanization, monthly income, severity of diabetes, and risk factor for AA. We identified variable classes of OADs, including metformin, sulfonylureas, thiazolidinedione (TZD), alpha-glucosidase inhibitors, meglitinide, dipeptidyl peptidase-4 (DPP-4) inhibitors prior to the development of AA.
resultsA total of 4468 cases diagnosed with AA and 4468 matched controls were identified. Metformin use, sulfonylurea use, and TZD were associated with lower risk of developing AA, odds ratio [OR] 0.72 (95 % confidence interval [CI] 0.64-0.80), 0.82 (95 % CI 0.74-0.92), and 0.82 (95 % CI 0.69-0.98), respectively. The effects of metformin and sulfonylurea on AA were dose responsive. Neither alpha-glucosidase inhibitors (OR 0.95; 95 % CI 0.81-1.11) nor DPP-4 inhibitors (OR 0.85; 95 % CI 0.68-1.07) was significantly associated with AA events.
conclusionsMetformin, sulfonylurea, and TZD treated patients were associated with lower risks of AA development, but not DPP-4 inhibitors or alpha-glucosidase inhibitor. The protective effects of hypoglycemic agents are further confirmed by the dose responsive relations in metformin and sulfonylurea groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.